The Power of Your Body Defense Exploring Immunotherapy in Medical Oncology

The immune system is one of the body's most sophisticated defence mechanisms. It constantly identifies and responds to threats such as infections and abnormal cells. However, cancer cells can develop ways to avoid immune detection or suppress the immune response, allowing them to grow and survive.

Immunotherapy has changed the way doctors approach several types of cancer by helping the immune system recognise and respond to malignant cells more effectively. It does not work for every cancer or every patient, but for people who are suitable candidates, it can become an important part of modern cancer treatment.

Understanding how immunotherapy works, who may benefit and what side effects to expect can help patients make more informed decisions with their oncology team.

How Does Immunotherapy Activate the Immune System?

Cancer cells can use biological signals to interfere with the immune system's ability to attack them. One way they do this is by exploiting immune checkpoint pathways.

Immune checkpoints are normal mechanisms that prevent the immune system from becoming excessively active and damaging healthy tissues. Some cancers can take advantage of these pathways to avoid immune attack.

Immune checkpoint inhibitors work by blocking certain checkpoint proteins, such as PD-1, PD-L1 or CTLA-4. This can allow immune cells, particularly T cells, to remain active against cancer cells.

Rather than directly destroying cancer cells in the same way as many chemotherapy medicines, checkpoint inhibitors help restore or strengthen an existing immune response.

However, this does not mean that immunotherapy simply "trains" the immune system to attack every cancer. Its effectiveness depends on several factors, including the cancer type, tumour biology and the patient's individual immune response.

How Doctors Decide Whether Immunotherapy Is Appropriate

Immunotherapy is not suitable for every patient. Before recommending it, the oncology team considers the cancer type, stage, previous treatments, overall health and relevant tumour biomarkers.

Depending on the cancer, testing may include:

• PD-L1 expression
• Microsatellite instability (MSI)
• Mismatch repair deficiency (dMMR)
• Tumour mutational burden (TMB)
• Specific genetic alterations or other biomarkers

The importance of each biomarker varies according to the type of cancer and the specific immunotherapy being considered.

Pathologists may examine tumour tissue to identify these characteristics. In some situations, blood-based or other molecular tests may also provide useful information.

A positive biomarker does not guarantee that immunotherapy will work, just as a negative result does not necessarily mean that every immunotherapy option is ruled out. Treatment decisions should be made by the oncology team based on the complete clinical picture.

Immunotherapy vs Chemotherapy

Chemotherapy and immunotherapy work in fundamentally different ways.

Many chemotherapy medicines directly interfere with cancer-cell growth or division. Because some healthy cells also divide rapidly, chemotherapy can cause side effects involving tissues such as the hair follicles, digestive tract and bone marrow.

Immunotherapy, on the other hand, works primarily by modifying or enhancing immune activity against cancer.

This does not necessarily mean that immunotherapy is easier for everyone. Some patients tolerate it well, while others can develop significant immune-related complications.

The right treatment depends on the specific cancer rather than whether one approach is considered universally "better" than another.

What Should Patients Expect During Immunotherapy?

Immunotherapy is commonly administered through an intravenous infusion, although some cancer treatments involving immune-based mechanisms may be available in other forms.

The treatment schedule depends on the medicine and type of cancer. Some therapies are given every few weeks, while others follow different schedules.

Patients may not experience an immediate change in how they feel. Cancer response is generally assessed through clinical evaluation, imaging and laboratory tests at appropriate intervals.

Importantly, immunotherapy does not always produce the same response pattern as conventional treatments. In some cases, immune cells can temporarily accumulate around a tumour, making it appear larger on imaging before a later response becomes evident. This phenomenon is sometimes referred to as pseudoprogression.

However, not every increase in tumour size represents pseudoprogression. Doctors consider the patient's symptoms, imaging findings and overall clinical picture before deciding whether treatment should continue.

Understanding the Side Effects of Immunotherapy

Immunotherapy has its own characteristic side-effect profile.

Because these medicines activate or modify the immune response, the immune system can sometimes attack healthy tissues. These are known as immune-related adverse events.

Depending on the organ involved, patients may experience:

• Skin rashes or itching
• Diarrhoea or inflammation of the bowel
• Liver inflammation
• Thyroid or other hormonal problems
• Lung inflammation
• Joint or muscle symptoms
• Fatigue

Most side effects are manageable when recognised early, but some can become serious if treatment is delayed.

Patients should therefore tell their healthcare team about new or unusual symptoms rather than assuming they are a normal part of cancer treatment.

How Are Immune-Related Side Effects Managed?

Management depends on the severity and organ involved.

Doctors may temporarily pause immunotherapy and perform additional tests to determine the cause of the symptoms. When significant immune-related inflammation occurs, corticosteroids or other immunosuppressive medicines may be used.

Not every symptom requires steroids, and treatment decisions depend on the specific clinical situation.

Early communication is particularly important. A new persistent cough, significant diarrhoea, severe rash, jaundice, unusual weakness or changes in hormone-related symptoms should be reported promptly.

Immunotherapy and Combination Treatments

Immunotherapy may sometimes be combined with other cancer treatments.

Depending on the cancer, combinations may include:

• Immunotherapy and chemotherapy
• Immunotherapy and targeted therapy
• Two different immunotherapy medicines
• Immunotherapy with radiation therapy
• Immunotherapy with surgery in selected treatment settings

The purpose of combination treatment varies. In some cancers, chemotherapy or radiation may alter the tumour environment in ways that complement immune-based treatment. In other situations, combining treatments may improve cancer control.

However, combination therapy can also increase side effects. Therefore, the potential benefits and risks must be carefully evaluated for each patient.

The Importance of Specialist Oncology Care

Immunotherapy requires careful patient selection and ongoing monitoring. A medical oncology doctor evaluates whether the treatment is appropriate, selects the relevant medicine and monitors both cancer response and potential complications.

When choosing a best medical oncology doctor, patients may consider:

• Experience with their specific type of cancer
• Access to molecular and biomarker testing
• Experience with immunotherapy
• Availability of multidisciplinary cancer care
• Facilities for managing treatment-related complications
• Access to clinical trials where appropriate
• Long-term follow-up and supportive care

For patients considering a Best Hospital in Gurgaon, the availability of experienced oncology teams, infusion facilities, diagnostic support and emergency care can be important factors when comparing treatment centres.

What About Clinical Trials?

Cancer research continues to explore new immunotherapy medicines and treatment combinations.

Clinical trials may investigate:

• New checkpoint inhibitors
• Novel immune targets
• Personalised cancer vaccines
• Cellular therapies
• Combination treatment approaches
• New ways to identify patients who are most likely to respond

Participation in a clinical trial is not automatically better than standard treatment. However, for some patients, an appropriate trial can provide access to a treatment that is not yet routinely available.

Patients interested in clinical trials should discuss eligibility, potential benefits, risks and alternatives with their oncology team.

Life After Immunotherapy

Completing immunotherapy does not always mean that medical follow-up ends.

Depending on the type and stage of cancer, patients may require ongoing imaging, blood tests, physical examinations and monitoring for delayed side effects.

The follow-up schedule varies considerably between individuals.

Maintaining healthy lifestyle habits can also support overall wellbeing. A balanced diet, appropriate physical activity, adequate sleep and emotional support can all contribute to recovery and quality of life.

However, lifestyle measures should complement—not replace—evidence-based cancer treatment.

Looking Towards the Future

Immunotherapy has become an important part of modern oncology, offering meaningful treatment options for selected patients with several types of cancer.

At the same time, it is important to maintain realistic expectations. Not every tumour responds to immunotherapy, and responses can vary significantly between patients. Researchers continue to study why some cancers respond well while others develop resistance or fail to respond.

The future of cancer treatment is likely to involve increasingly personalised combinations of therapies based on tumour biology and individual patient characteristics.

Final Thoughts

Immunotherapy represents a major development in medical oncology by using the body's own immune system as part of the fight against cancer. Treatments such as immune checkpoint inhibitors have changed the outlook for some patients with advanced and earlier-stage cancers.

But immunotherapy is not a universal cancer treatment. Its suitability depends on the type of cancer, its molecular characteristics, stage, previous treatments and the patient's overall health.

If immunotherapy is being considered for you or someone close to you, discuss the potential benefits, risks, alternatives and expected outcomes with a qualified oncology team. Careful evaluation and regular monitoring are essential for making the most of this evolving approach to cancer treatment.